In this Issue:
Nivolumab and ipilimumab vs monotherapy in untreated melanoma
Pembrolizumab vs ipilimumab in advanced melanoma
Long-term survival data from trials of ipilimumab in advanced melanoma
Dabrafenib and trametinib vs dabrafenib only for Val600 BRAF-mutant melanoma
Adjuvant ipilimumab after complete resection of high-risk stage III melanoma
Ipilimumab treatment in patients with metastatic melanoma who have progressed on anti-PD-1 therapy
The cost of ipilimumab toxicity
Atypical patterns of response in patients with metastatic melanoma treated with pembrolizumab
Pembrolizumab in melanoma patients with untreated brain metastases
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
Please login below to download this issue (PDF)